Du er på: newsweb.no
Fra dato
Til dato
Velg marked
Vis kun aktive utstedere Info...
MeldingsID: 278275
Dato/tid 18.03.2011 09:22
Utsteder Photocure ASA
UtstederID PHO
Marked OB
Informasjonspliktig   Informasjonspliktige opplysninger   Lagringspliktig melding
Tittel Photocure - British Journal of Urology publishes paper on Hexvix®

       Photocure - British Journal of Urology publishes paper on Hexvix®
       Demonstrates significant reduction in recurrence of bladder cancer

Oslo,  Norway 18 March  2011: Photocure (OSE:  PHO), a  Norwegian pharmaceutical
company  specialising in dermatology and cancer,  announces the publication of a
paper  on Hexvix®  in the  peer-reviewed British  Journal of Urology (BJU). This
publication demonstrates that Hexvix®-guided cystoscopy (Hexvix®), as an adjunct
to conventional white-light cystoscopy, improves the detection of bladder cancer
and  reduces the rate of recurrence as compared to white-light cystoscopy alone.
Hexvix  is  the  first  approved  drug  for  diagnosis of bladder cancer. Hexvix
enhances  detection  of  bladder  cancer  and  enables doctors to carry out more
effective tumor removal.

The  publication is  based on  a prospective,  randomised clinical trial in 233
patients  which was conducted  by Photocure in  two centres in Denmark. Patients
were  randomized to either  standard white-light transurethral  resection of the
bladder  (TURB) or standard white-light TURB  followed by Hexvix. In this study,
lesions  identified with standard  white-light cystoscopy and  TURB were removed
prior to the Hexvix guided cystoscopy and TURB.

The  results of the trial demonstrate  that Hexvix identified lesions (including
residual  tumors) that were  not detected with  white light alone  in 49% of the
patients.  It also demonstrated that the  improved detection of lesions resulted
in a significant reduction in tumour recurrence within 12 months.

In  the study, 31% of patients who had  Ta or T1 tumors at inclusion experienced
recurrence  with  Hexvix-guided  cystoscopy  compared  to  47% with  white-light
cystoscopy  (p=0.05), a  relative reduction  in recurrence of 36%. Additionally,
the recurrence free interval was significantly longer for patients in the Hexvix
arm (p=0.02).

"This  study demonstrates  that Hexvix-guided  cystoscopy improves the detection
and resection of non-muscle invasive bladder cancer when compared to white-light
cystoscopy  alone, and that these improvements lead to a reduction in the tumour
recurrence  after 12 months of  follow up" states  Gregers Hermann MD, F.E.B.U.,
Frederiksberg Hospital, principal investigator.

Bladder  cancer has  the highest  rate of  recurrence of  all cancer types. This
results  in a very high prevalence of  disease which requires patients to return
for regular follow-ups and treatment.

The  results  of  this  study  confirm  the  results  from  a  large prospective
international  study published in the Journal  of Urology in November 2010. This
is  the second  study to  demonstrate that  the improved detection of non-muscle
invasive  bladder  cancer  with  Hexvix  cystoscopy  leads to a reduction of the
bladder cancer recurrence.

For further information, please contact:

President & CEO Kjetil Hestdal
Tel: + 47 913 19 535, Email:kh@photocure.no
CFO Christian Fekete
Tel: + 47 916 42 938, Email:cf@photocure.no

Capital MS&L
Mary Clark, Justine Lamond and Hollie Vile
Tel: +44 (0)20 7307 5337, Email:Photocure@capitalmsl.com

About Photocure ASA
Photocure  ASA is a worldwide leader in photodynamic therapy. Listed on the Oslo
Stock  Exchange  (OSE:  PHO),  Photocure  develops and sells pharmaceuticals and
medical  devices  for  the  photodynamic  treatment  and diagnosis of cancer and
selected  dermatology indications. The  company strives to  solve unmet needs by
developing  new  and  innovative  solutions  based  on  its  patented  Photocure
Technology(TM). Photocure markets and sells its own products in selected markets
and has developed strong partnerships with leading pharmaceutical companies on a
regional  and  global  basis.  Photocure's  bladder  cancer  diagnostic product,
Hexvix®  is approved in the European Union and the US. Setting new standards for
diagnosis   and   treatment   of   several   different   conditions,   Photocure
Technology(TM)  is very selective, targeting  only diseased cells and preserving
healthy  tissue. Photocure Technology(TM)  is being tested  for new products and
indications  including acne,  improving the  appearance of  skin (Allumera(TM)),
diagnosing colon cancer (Lumacan® which is outlicensed to Salix Pharmaceuticals)
and the treatment of pre-malignant cervical lesions (Cevira®).

Photocure,  Inc. is the marketing  and sales subsidiary of  Photocure ASA in the
US. It is located in Princeton, NJ.

This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)


Les om ansvar og rettigheter.